CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy

• Published in: Oncoimmunology Vol. 13; no. 1; p. 2338965
• Main Authors: Pant, Ayush, Hwa-Lin Bergsneider, Brandon, Srivastava, Siddhartha, Kim, Timothy, Jain, Aanchal, Bom, Sadhana, Shah, Pavan, Kannapadi, Nivedha, Patel, Kisha, Choi, John, Cho, Kwang Bog, Verma, Rohit, Yu-Ju Wu, Caren, Brem, Henry, Tyler, Betty, Pardoll, Drew M, Jackson, Christina, Lim, Michael
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2024; Taylor & Francis Group
• Subjects: Animals; Brain Neoplasms - drug therapy; Glioblastoma - drug therapy; Glioma; Glioma - drug therapy; Humans; Immunotherapy; MDSC; Mice; Myeloid Cells - pathology; Myeloid-Derived Suppressor Cells; Original Research; Receptors, CCR2; Receptors, CCR5 - therapeutic use; Tumor Microenvironment; Glioma; Immunotherapy; MDSC
• ISSN: 2162-402X; 2162-4011; 2162-402X
• DOI: 10.1080/2162402X.2024.2338965

Immunotherapy has revolutionized the treatment of cancers. Reinvigorating lymphocytes with checkpoint blockade has become a cornerstone of immunotherapy for multiple tumor types, but the treatment of glioblastoma has not yet shown clinical efficacy. A major hurdle to treat GBM with checkpoint blockade is the high degree of myeloid-mediated immunosuppression in brain tumors that limits CD8 T-cell activity. A potential strategy to improve anti-tumor efficacy against glioma is to use myeloid-modulating agents to target immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. We found that the co-inhibition of the chemokine receptors CCR2 and CCR5 in murine model of glioma improves the survival and synergizes robustly with anti-PD-1 therapy. Moreover, the treatment specifically reduced the infiltration of monocytic-MDSCs (M-MDSCs) into brain tumors and increased lymphocyte abundance and cytokine secretion by tumor-infiltrating CD8 T cells. The depletion of T-cell subsets and myeloid cells abrogated the effects of CCR2 and CCR5 blockade, indicating that while broad depletion of myeloid cells does not improve survival, specific reduction in the infiltration of immunosuppressive myeloid cells, such as M-MDSCs, can boost the anti-tumor immune response of lymphocytes. Our study highlights the potential of CCR2/CCR5 co-inhibition in reducing myeloid-mediated immunosuppression in GBM patients.